GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » YoY EPS Growth

Actelion (Actelion) YoY EPS Growth : 11.06% (As of Mar. 2017)


View and export this data going back to . Start your Free Trial

What is Actelion YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Actelion's YoY EPS Growth for the quarter that ended in Mar. 2017 was 11.06%.

Actelion's Earnings per Share (Diluted) for the three months ended in Mar. 2017 was $1.86.


Actelion YoY EPS Growth Historical Data

The historical data trend for Actelion's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion YoY EPS Growth Chart

Actelion Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 311.68 57.28 19.39 -5.82 28.44

Actelion Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.75 44.18 37.47 15.57 11.06

Actelion YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Actelion's YoY EPS Growth for the fiscal year that ended in Dec. 2016 is calculated as:

YoY EPS Growth (A: Dec. 2016 )
=(Earnings per Share (Diluted) (A: Dec. 2016 )-Earnings per Share (Diluted) (A: Dec. 2015 ))/ | Earnings per Share (Diluted) (A: Dec. 2015 ) |
=(6.337-4.934)/ | 4.934 |
=28.44 %

Actelion's YoY EPS Growth for the quarter that ended in Mar. 2017 is calculated as:

YoY EPS Growth (Q: Mar. 2017 )
=(Earnings per Share (Diluted) (Q: Mar. 2017 )-Earnings per Share (Diluted) (Q: Mar. 2016 )) / | Earnings per Share (Diluted) (Q: Mar. 2016 )) |
=(1.857-1.672)/ | 1.672 |
=11.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actelion YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Actelion's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Actelion (Actelion) Business Description

Traded in Other Exchanges
N/A
Address
Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Actelion Still On Growth Track

By reports.droy reports.droy 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 01-24-2017

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon 02-14-2017

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson 08-03-2016